https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-622009-04-01 00:00:002021-11-15 17:02:15Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-30 / Eur. Urol. 2009 Jun;55(6):1333-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-30 / Eur. Urol. 2009 Jun;55(6):1333-422009-01-30 00:00:002021-11-15 14:46:31Vaccine therapy in patients with renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-01 / Methods Mol. Biol. 2009;542:565-605
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-01 / Methods Mol. Biol. 2009;542:565-6052009-01-01 00:00:002021-11-15 17:03:01Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-01 / Expert Rev Vaccines 2009 Jan;8(1):51-66
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-01 / Expert Rev Vaccines 2009 Jan;8(1):51-662009-01-01 00:00:002021-11-15 17:02:36Randomized clinical studies of anti-tumor vaccination: state of the art in 2008
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-900
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-9002008-11-08 00:00:002021-11-15 17:03:25Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-10-01 / Int. J. Oncol. 2008 Oct;33(4):823-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-10-01 / Int. J. Oncol. 2008 Oct;33(4):823-322008-10-01 00:00:002021-11-15 17:03:44Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-05 / Virus Res. 2008 Sep;136(1-2):75-80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-05 / Virus Res. 2008 Sep;136(1-2):75-802008-06-05 00:00:002021-11-15 17:04:06Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-03 / Ann. Surg. Oncol. 2008 Aug;15(8):2310-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-03 / Ann. Surg. Oncol. 2008 Aug;15(8):2310-72008-06-03 00:00:002021-11-15 17:04:28Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-17 / Cancer Immunol. Immunother. 2009 Jan;58(1):61-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-17 / Cancer Immunol. Immunother. 2009 Jan;58(1):61-92008-05-17 00:00:002021-11-15 17:04:52Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-15 / Clin. Cancer Res. 2008 May;14(10):3098-104
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-15 / Clin. Cancer Res. 2008 May;14(10):3098-1042008-05-15 00:00:002021-11-15 14:47:03Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme
